Literature DB >> 12641330

Application of spectrofluorometry for evaluation of dry powder inhalers in vitro.

T Srichana1, R Suedee, P Srisudjai.   

Abstract

Andersen cascade impactor (ACI) is commonly used for the testing of pharmaceutical aerosols, which has to be coupled with an instrument for quantitative analysis of drug depositing on each stage of the ACI. This procedure consumes much time in operation. Therefore, this study was aimed at speeding up the process of drug analysis in aerosol formulations after obtaining samples from the ACI. From the results obtained, it was proved that the validated spectrofluorometric method was accurate and sensitive. It was capable of giving similar results to those we obtained from HPLC-UV analysis. There was no interference from the amount of lactose carrier incorporated in the formulation in the step of salbutamol analysis indicating specificity of the method. As a result, samples were analyzed without further separation. The detection limit was 0.1 microg/ml. Hence, spectrofluorometry can be used as a substitute method to HPLC-UV in determining the small quantity of salbutamol after aerosolization from dry powder aerosols. The present study suggests that spectrofluometry can be a rapid and efficient method in the pharmaceutical analysis of aerosols.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641330

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  2 in total

1.  Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.

Authors:  Wipaporn Rojanarat; Narumon Changsan; Ekawat Tawithong; Sirirat Pinsuwan; Hak-Kim Chan; Teerapol Srichana
Journal:  Int J Mol Sci       Date:  2011-07-07       Impact factor: 5.923

2.  Levofloxacin-proliposomes: opportunities for use in lung tuberculosis.

Authors:  Wipaporn Rojanarat; Titpawan Nakpheng; Ekawat Thawithong; Niracha Yanyium; Teerapol Srichana
Journal:  Pharmaceutics       Date:  2012-08-13       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.